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Abstract
Purpose—Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection is an
important and frequent scenario, predominantly in injecting drug users (IDUs). The present study
evaluated morbidity and mortality variation in HIV infected patients with and without HCV
coinfection.
Methods—Coinfection prevalence was determined in 356 HIV infected persons. Their clinical
manifestations, laboratory findings, risk factors, HIV therapies and mortality rates were evaluated.
Results—HCV prevalence was 54% in the overall group and 81% in IDUs, with predominance
of HCV genotype 1. Mortality rates were similar in patients with and without coinfection;
however coinfected patients had significantly higher liver damage as a cause of mortality when
compared with those who were not coinfected.
Conclusions—The high HCV prevalence and the emerging mortality from liver diseases,
revealed the significance of this coinfection in HIV epidemic. Primary and secondary prevention
are necessary to reduce the expanding impact of HCV infection in HIV patients.
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INTRODUCTION
The introduction of highly active antiretroviral therapy (HAART) has increased the life
expectancy among subjects infected with the human immunodeficiency virus (HIV). The
primary reason for the increased longevity is the declining rates of opportunistic infections,
which often were one direct cause of demise. This scenario has introduced a number of
issues, which are interdisciplinary in nature and will define newer aspects on the HIV
epidemic until a viral eradication is a possibility. Some of these issues concern the
emergence of chronic conditions which are compatible with a prolonged survival. The
presence of Hepatitis C viral (HCV) infection is one of the chronic infections that are often
seen co infecting HIV patients, particularly in subject who are injecting drug users
(IDUs).1--11
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Between 30% to over 50% of HIV infected persons have a concurrent HCV
coinfection.1,10,11 The impact of the coinfection appears to be more relevant in certain
ethnic groups and particularly amongst IDUs. In this latter group the prevalence exceeds
80% with important variations according to the patients’ age and the duration of the risk
practice.11--13
Many of the details regarding the interaction between HIV and HCV remain controversial.
Certain studies suggest that HCV related hepatic damage is worsened in patients with HIV
infection and that HCV mutates more readily in HIV patients with low CD4+ lymphocyte
count.14--16 A more controversial point is the impact of HCV infection on the course of HIV
infection. Several studies suggest that HCV does not affect the natural history of HIV
infection. Some authors found that coinfection does not influence the rate of progression to
either clinical or immunologic endpoints in coinfected HIV patients.17--19 Other studies
suggest that the coinfection worsens the immunologic deterioration and thus accelerates the
progression to AIDS.20--22 An important variable that is emerging in the literature is the
impact that variations in the HCV genotype may have on the progression of HIV infection.
HCV genotype 1a and 1b have been reported to be more often associated to a rapid
progression to AIDS and death than other genotypes.11
The present paper evaluates differences of HCV coinfected and not coinfected in a cohort of
HIV/AIDS patients followed in Puerto Rico.
MATERIALS AND METHODS
Study population
The study population was comprised by 519 HIV infected patients that entered the
Retrovirus Research Center (RRC) cohort between February 1998 and August 2000. All
persons were invited to participate, 365 accepted, and 356 (69% of 519) completed the HCV
laboratory tests. Case recruitment and follow up were performed at the Ramón Ruiz Arnau
University Hospital at Bayamón, Puerto Rico or in the HIV ambulatory clinics. Once an
informed consent was obtained, a baseline questionnaire was completed and appropriate
laboratory tests were performed. Data were gathered via personal interviews and medical
record review and abstraction. A questionnaire which includes socio-demographic, HIV risk
factors, clinical manifestations, antiretroviral therapy (ART), laboratory findings and
mortality was used to collect the data. Presumptive and confirmed diagnosis of opportunistic
infections such as esophageal candidiasis, Pneumocystis jirovecii pneumonia (PJP), cerebral
toxoplasmosis, recurrent bacterial pneumonia, pulmonary tuberculosis, Kaposi sarcoma,
herpes simplex virus and wasting syndrome were recorded. A complete explanation of the
RRC questionnaires is described by Gómez and collaborators.23 Highly Active
Antiretroviral Therapy (HAART) was defined as patients with three or more antiretroviral
treatments at study entry. Selected candidates were patients over 18 years old, in whom a
HCV qualitative test was performed. HCV viral load and HCV genotype were additionally
done in HCV positive cases. Those cases with detectable HCV viral load composed the
coinfected study group. The remaining cases formed the not coinfected group. The death
status of the study participants as of December 2003 was used to measure the mortality of
the study group.
Laboratory measures
The following laboratory test were performed at study entry.
CD4+ Lymphocyte measurement by flow cytometry—A four-color modular
flowcytometry analyzer (FACSCalibur Becton/Dickinon, San Jose, CA) was used for CD4+
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cell count. For this assay, peripheral blood samples were collected in the presence of EDTA
and prepared utilizing a lysed whole blood method. Samples were stained with murine
monoclonal antibodies directly conjugated with flourochrome FOTC and PE (Simultest
reagents, Becton/ Dickinson) for the quantitation of CD3 (total T cells) and CD3/CD4
lymphocyte.
HIV and HCV virion RNA quantitation—HIV viral load was determined by RNA RT-
PCR (Amplicor HIV monitor v.2, Roche Diagnostic System Inc, Indianapolis, IN). This test
has a sensitivity of 400 to 750,000 copies/ml. Those specimens with a viral titer of less than
400 were tested with the Roche’s RT-PCR modified ultrasensitive version which has a
detection range of 50 to 75,000 copies/ml. HCV viral load was determined by RNA RT-
PCR (COBAS Amplicor HCV Monitor, Roche Diagnostic Inc,). This test has a detection
limits between 100 and 500,000 International Units (IU)/ml. Some of the samples with a
viral load below 100 copies/ml were tested with the Taq Man RNA Real Time PCR (Roche
Diagnostic System Inc) that has a detection range of 10 to 200 × 106 IU/ml.
HCV genotyping—The Bayer’s Truegene HCV Genotyping sequencing method
(Norcross, GA) was performed on PCR-amplified product for the HCV genotype/subtype
determination. For all these analysis, appropriate controls were included.
Mortality
Mortality data were obtained from a review of the institutional medical records and from the
Puerto Rican AIDS surveillance system. In addition the mortality registry of the Puerto
Rican Health Department was reviewed in order to confirm the death status of the
participants. The reported causes of death were tabulated and organized into several
categories. These categories included: 1) systems or organ failure (Cardio-vascular,
Pulmonary, Gastrointestinal, Renal, Neurological and Metabolic), 2) AIDS conditions (PJP,
cerebral toxoplasma and wasting syndrome) and 3) drug overdose or poisoning. A subgroup
of liver conditions which included liver failure (chronic and acute) and cirrhosis was
included.
Statistical analysis
The Statistical Package of Social Sciences (SPSS) program was used to perform univariate,
bivariate and multivariate analyses. Univariate analysis described the frequencies of clinical
conditions, immunological findings and antiviral drugs regimens used. Quality differences
between patients with and without coinfection were analyzed with the Chi-square or Fisher
exact test. ANOVA and student t test were used to evaluate means differences. Mann
Whitney test, a non parametric test, was used to evaluate median differences between
groups. Group differences were also evaluated after stratifying by the use of injecting drug
(IDU) as HIV risk factor.
Differences in mortality rates, causes of death and disease duration were evaluated and
analyzed in the HIV cohort. Time of follow-up was defined as the time between the patient’s
enrollment and their death or as of December 2003. HIV disease duration was defined as the
time between the first documented positive HIV test and the last follow up or death of the
patient. Kaplan Meier analysis was performed to explore the variation in the survival time.24
The influence of covariate factors was studied with the help of Cox proportional-hazards
analysis.25 P value level used to determine statistical significance was less than 0.05.
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Of the 356 HIV infected patients entered into the study, 193 (54.0%) had HCV viral load
greater than 100 copies/ml. Of the 356 HIV infected patients, 249 (69.9%) were male and
the mean age at enrollment was 37.6 ±8.8 years. Injecting drug used (IDU) as the main risk
factor for HIV infection was reported in 57.6% of the patients. This risk factor was slightly
higher than that reported for the overall RRC cohort (51.7%). At study enrollment, 16
(4.6%) of the patients had history of PJP, 21 (5.9%) cerebral toxoplasmosis, 16 (4.5%)
recurrent pneumonia, 5 (1.4%) pulmonary tuberculosis, 2 (0.6%) Kaposi sarcoma and 49
(13.8%) had wasting syndrome. The median CD4+ cell count was of 150 cells per ml and
over 57% of the patients had a CD4+ cell count below 200 cells per ml. The median CD8+
cell count was of 660 cells per ml with a median CD4/CD8 ratio of 0.24. The median white
blood cell count per ml was of 5,400 cells per ml with an absolute lymphocyte count median
of 1,200 cells per ml. The median HIV viral load was 10.8 × 104 copies per ml. Over 43% of
the cases were ART naive at study entry. Conversely, over 44% of patients were on HAART
at study entry. As of December 2003, 168 of the 356 study patients (47.2%) were dead. This
mortality was slightly lower than that reported for the overall RRC cohort (52.5%).
Group differences
Table 1 presents the most relevant parameter differences between the 193 HCV coinfected
and the 163 not coinfected patients. Both groups had similar mean age (37.1 ± 7.9 vs. 38.2 ±
9.7, p = 0.256). The coinfected group had a higher proportion of men (79.8% vs. 58.3%, p <
0.01) and IDUs (85.5% vs. 24.5%, p < 0.01). The median time of injecting drug use was
similar in both groups (17.8 years in coinfected and 18.4 years in not coinfected). Men
having sex with men were less frequently reported in coinfected (8.5% vs. 33.3%, p < 0.01).
The prevalence of the AIDS defining conditions at study enrollment were; PJP (3.1% vs.
6.1%), recurrent pneumonia (3.1% vs. 6.1%), wasting syndrome (11.9% vs. 16.0%) and
esophageal candidiasis (3.6% vs. 6.1%). These conditions were lower in coinfected group
although statistical significance was not reached. A higher median CD4 + cell count (189 vs.
120) and a lower median HIV viral load (10.5 × 104 vs. 11.5 × 104) were seen in the
coinfected group. The HIV/HCV coinfected individuals had lesser clinical and
immunological evidence of HIV infection. Antecedent of HAART at enrollment was similar
in both groups (42% vs. 48%, p = 0.207). However, their compliance and adherence could
not be measured. Conversely, the mortality rate was slightly higher in the coinfected groups
(57.7% vs. 51.1%), but this difference did not reach statistical significance.
Of the 356 study cases, 205 were IDUs and 81% of them were HCV sero-positive (Table 2).
Coinfected IDUs had higher prevalence of men (82.4% vs. 72.5) and lower prevalence of
PJP (3.6% vs. 5.0%), recurrent pneumonia (3.6% vs. 10.0%), and wasting syndrome (12.7%
vs. 27.5%) when compared to not coinfected IDUs. The median CD4+ cell count (180 vs.
120) and the HIV vial load median (10.7 × 104 vs. 10.3 × 104) were slightly higher in this
coinfected group. Only the wasting syndrome difference reached statistical significance.
HAART antecedent (35.8% vs. 35.0%) and mortality rates (51.5% vs. 55.0%) were similar
in these IDUs’ groups.
On the other hand, 28 (18.5%) of the 150 non-IDUs were positive for HCV (Table 2). These
coinfected patients had lower rates of AIDS defining conditions, higher CD4+ cell count
median (210 vs. 128, p < 0.05), lower HIV viral load median (8.3 × 104 vs. 11.5 ×
104copies) and higher antecedent of HAART used (78.6% vs. 52.0%, p < 0.05), than the not
coinfected, non-IDUs. Mortality rate was slightly higher in this coinfected group (42.9% vs.
39.8%, p > 0.05). In addition, the study found a higher HCV viral load median in coinfected
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cases who were IDUs when compared to non-IDUs (50 × 104 vs. 31.6 × 104 copies/ml).
However, this difference was not statistically significant.
HCV genotypes
Of the 193 coinfected study cases, 164 were tested for HCV genotype. Genotype 1 was the
most prevalent (82.3%), followed by genotype 3 (8.5%), genotype 4 (3.7%) and genotype 2
(3.1%). In four cases (2.4%) the genotype was indeterminate. In those where the genotype
was determinate, the most prevalent virus subtypes were: 1a (53.1%), 1b (31.3%) and 3a
(8.9%). Genotype 1 was more prevalent in the IDUs than in the non IDUs (88.9% vs.
80.0%). Patients with genotype 1 had higher HCV viral median load (53 × 104 copies per ml
vs. 40.1 × 104 copies per ml), higher HIV viral median load (12.7 × 104 copies per ml vs.
4.9 × 104 copies per ml) and lower CD4+ cell count median (188 cells per ml vs. 200 cells
per ml) (data not shown). These differences did not reach statistical significance. We did not
detect any other changes in the morbidity or mortality of patients when analyzed according
to HCV genotypes.
Mortality
As of December 31, 2003 a total of 168 of the 356 study cases were known to be dead. A
Cox proportional hazard analysis revealed that patients with a CD4+ cell count of less than
200/ml, or with antecedents of wasting syndrome had a significant increment in the
mortality risk (Table 3). The antecedents of HAART and PJP prophylaxis at study entry
produced a non significant decrement in the mortality risk. It can also be stated that the
presence of HCV coinfection or the IDU as a risk factor produced a non significant
increment of the mortality risk. In the analysis of causes of death, several significant
differences were seen between HIV/HCV coinfected and not coinfected persons. Of the 168
patients who died, 97 (57.7%) were HCV positive and 71 (42.3%) were HCV negative. As
shown in Table 4, male gender (83.5% vs. 57.7%) and the antecedent of IDU were more
prevalent in the coinfected death cases (87.6% vs. 31.0%). Men having sex with men were
associated with a lower mortality in the coinfected cases (6.2% vs. 29.3%). Coinfected death
cases had longer HIV disease duration (4.1 years vs. 3.2 year), slightly higher antecedent of
HAART (40.2% vs. 36.6%) and lower AIDS prevalence (68.0% vs. 88.7%) at study entry
than not coinfected death cases. Causes of death related to hepatic dysfunction, cirrhosis or
failure were significantly higher in the HCV infected persons (19.6% vs. 1.4%). In general,
the presences of gastrointestinal conditions as causes of death were seen more often in the
coinfected patients as compared to the other group (28.9% vs. 9.9%). Liver related
dysfunction as a cause of death was more commonly reported in patients infected with HCV
genotype 1 as compared to other HCV genotypes (19.1% vs. 7.7%, p > 0.05) (Data not
shown). On the other hand, coinfected cases had significantly lower rate of pulmonary
conditions such as pneumonia (38.1% vs. 57.7%) reported as the cause of death in their
certificates as compared to the non-coinfected group.
DISCUSSION
The implementations of HAART along with an increase in the presence of chronic
conditions of the HIV survivors are producing important changes in the natural history of
HIV/AIDS. These changes deserve evaluation. The coinfection with HIV and HCV is
emerging as an important and frequent finding in patients seeking therapy for one or the
other viral entity. The fact that both viruses share a similar route of transmission and
mechanisms of epidemic spread appears to be the most important reason for the growing
nature of the coinfection.20--22 It is known that the highest prevalence of the coinfection is
occurring in patients with a current or previous history of injecting drug used. The HIV
cohort of the Bayamón RRC is characterized by a high prevalence of IDUs; as such the
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expanding nature of this coinfection becomes an important issue for our health care delivery
system. Our data revealed a coinfection prevalence of 54% for the entire group and 82.5% in
the IDUs. These findings are consistent with other published information, reporting a high
prevalence of the coinfection associated to the risk scenario and risk practices of IDUs.11--13
MacDonald and collaborators reported an HCV prevalence over 50% among this high-risk
group and Sulkowski and collaborators found a coinfection prevalence of 44.6% among
1,955 cases of the John Hopkins HIV cohort.11,26
Similar to the overall RRC cohort, we found a high mortality rate in the study group; despite
that no significant mortality differences between coinfected and not coinfected patients were
detected. The similarities in their clinical, immunological and therapeutic profile at
enrolment could explain this finding. However, comparable findings were previously
reported by Sulkowski and collaborators. These authors did not find evidence that HCV
coinfection alters significantly the risk of dying or developing AIDS in their HIV study
group.26
Klein and collaborators argued that the prevalence of IDU increases the morbidity and
mortality of HCV infection and prevents an improved health care outcome for this
patients.27 In our study we did not find a significant morbidity or mortality variation
between HCV coinfected individuals with and without this risk behavior. On the other hand,
contrary to the study of Klein and collaborators in which active drug use was unknown, 77%
of our IDUS were actively using drug. Nevertheless, the common presence of injecting drug
use, with its social, clinical and psychological dimensions adds an element of therapeutic
complexity which needs to be included in the management of these patients with risky
lifestyles and behaviors. In addition, the low HAART adherence and the fear of increasing
rate of HIV viral variants may allow a worse outcome in this population.27
Even though our mortality rates were not significantly different between groups, HCV
coinfection introduced significant variation in the causes of death amongst the study groups.
HCV coinfection produced a chronic liver damage in HIV patients and over 15% of them
developed a severe liver damage or cirrhosis. 28--34 Additionally, HIV/HCV coinfection has
been associated with more rapid liver failure progression.26 The present study found that
10% of coinfected patients developed severe hepatic conditions which likely led to their
demise. This specific hepatic related mortality was higher than that reported in previous
studies.2,26 For example, Darby and collaborators reported a 6.5% of death related to liver
damage in their coinfected hemophilic patients.2 This high prevalence of hepatic damage in
our group suggests the possibility that some of these patients had been coinfected for long
time prior to study enrollment. Furthermore, there were no routine HCV screening tests for
our patients prior to the present study.
HCV genetic heterogeneity is a known hallmark of this infection. While genotype “1a” is
the most common in our study, genotype “1b” was more commonly reported in the US
mainland.35 This geographic variation could be related to the way patients have acquired the
HCV infection. Genotype “1b”, spreads more frequently by blood transfusion while
genotype “1a” is more frequently related to the injecting drug use risky practice.29,35 The
higher prevalence of genotype “1a” in our study is in concordance with the high prevalence
of IDUs in this group. Prior studies have reported a higher morbidity and mortality in HCV
patients attributed to the genotype 1 virus.10,11,36,37 In addition, HCV genotype 1 has been
related to a lower response to the anti- HCV pharmacological therapy.37,38 Our study found
that coinfected patients with HCV genotype 1 presented more often liver related death than
patients coinfected with other genotype. However, the mortality rates were not significantly
different between patients coinfected with different HCV genotypes. On the other, hand, this
study could not evaluate the relationship between HCV genotypes and anti-HCV therapy
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outcome because none of the coinfected cases reported the use of antiviral therapy for HCV.
HCV therapy in HIV infected persons has substantial complications due to potential drug
interactions and treatment related toxicities.26,39--46 The high prevalence of IDUs in the
coinfected patients introduce additional barriers for HCV therapy. The initiation and
evaluation of anti-viral therapy for HCV in coinfected patients remains an important
challenge particularly for centers, like ours, that provide care to medically indigent patients.
The present study had some limitations which could introduce potential biases. These biases
could have affected the results and their interpretation. First: This was a prevalence and not
an incidence study. Thus the real disease duration is this study could not be estimated. This
issue could explain the high mortality found after a short period of follow up. On the other
hand the clinical, immunological and therapeutic measures were gathered at the time the
HCV testing was performed. No further measures were obtained. Consequently the effects
of the change of these variables through time were not evaluated. Second: The study group
was selected by convenience and not randomized. This issue could introduce some selection
biases. And third: No liver function tests such as SGOT or SGPT were measured. The
adherence and compliance to anti retroviral therapy were also not measured. Consequently,
we could not evaluate the impact of these variables in the study group.
Knowledge about the interaction between HIV and HCV infections has become increasingly
crucial to public health.7,22,26 Lack of knowledge in this area generates delay in the
opportune diagnosis and treatment of HCV, which could increase the possibility of severe
target organ damage such as the one detected in our patients. Most of our cases became
aware of their coinfection with their participation in our study, probably years after their
initial HCV inoculum. The urgent implementation of primary and secondary HCV
prevention strategies in HIV infected population is essential and necessary to reduce the rate
of coinfection and its complications, especially in those persons with high risks behavior.
Until now there is no vaccine to prevent the HCV infection; however risk reduction
intervention could reduce the virus dissemination and opportune HCV medical treatment
could reduce the extent liver damage caused by the HCV. On the other hand, the high
mortality and the low prevalence of HAART and PJP prophylaxis in this group of
immunocompromised patients illustrate the present limitations of their HIV management.
Most of these peoples were medically indigent with financial barriers that could affect
directly and indirectly their HIV management. Nevertheless, additional efforts are needed to
improve HIV management in order to prevent or reduce future disease complications.
Finally, further studies need to be done in HIV/HCV coinfection, in order to explore in more
detail the current prevention strategies and the therapeutic management of this condition.
Another area that needs extensive research is the potential detrimental effects of repeated re-
inoculums, with both viruses, in the context of IDUs.
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Table 1









  Males 79.8 58.3 < 0.01
Mean age (years) 37.1±7.9 38.2±9.7 0.256
Risk Factors
  IDU (%) 85.5 24.5 < 0.01
  IDU length median (years) 17.8 18.4 0.718
  Man with man sex (%) 8.5 33.30 < 0.01
Laboratories (median)
  CD4 + cells count/ml 189 120 0.261
  CD8 + cells count/ml 665 630 0.681
  CD4/CD8 Ratio 0.24 0.22 0.796
  WBC cells/ml 5.400 5.500 0.821
  HIV viral load/ml 105,760 115,020 0.241
  HCV viral load/ml 500,000 n/a
Clinical findings (%)
  PJPH 3.1 6.1 0.170
  Pulmonary tuberculosis 1.0 1.8 0.664
  Cerebral toxoplasmosis 5.7 6.1 0.862
  Recurrent pneumonia 3.1 6.1 0.170
  Kaposi sarcoma 0.5 0.6 1.000
  Wasting syndrome 11.9 16.0 0.271
  Esophageal candidiasis 3.6 6.1 0.269
  Pulmonary candidiasis 0 1.2 0.209
  Immunological AIDS 52.2 62.7 0.050
  AIDS (Total) 61.8 68.7 0.165
Treatments (%)
  HAART at enrollment 42.0 47.9 0.266
  PJPH prophylaxis 16.6 28.2 < 0.01
Outcome (%)
  Mortality rate 57.7 51.1 0.207
PJPH: Pneumocystis jirovecii Pneumonia
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Table 2
Demographic, risk factor, clinical manifestation and laboratory findings in IDUs and in No-IDUs HIV infected









  Males 82.4/72.5 64.3/53.7
Risk Factors (%)
  Man with man sex 3.7/20.7** 35.7/30.0
Laboratories (median)
  CD4 + cells count/ml 180/120 210/128♦
  CD8 + cells count/ml 640/440* 819/675
  CD4/CD8 Ratio 0.22/0.22 0.37/0.22
  WBC cell/ml 5,450/6,700 5,350/5,300
  HIV viral load/ml 107,370/102,860 83,630/115,020
  HCV viral load/ml 500,000/ - 315,890/ -
Clinical findings (%)
  PJPH 3.6/5.0 0/6.5
  Pulmonary tuberculosis 1.2/2.5 0/1.6
  Cerebral toxoplasmosis 6.7/7.5 0/5.9
  Recurrent pneumonia 3.6/10.0 0/4.9
  Kaposi sarcoma 0/0 3.6/0.8
  Wasting syndrome 12.7/27.5* 7.1/12.2
  Esophageal candidiasis 4.2/5.0 0/6.5
  Immunological AIDS 52.9/69.2 48.1/60.7
  AIDS 61.8/67.5 60.7/69.1
Treatments (%)
  HAART at enrollment 35.8/35.0 78.6/52.0♦
  PJPH prophylaxis 15.2/17.5 25.0/31.7
Outcome (%)
  Mortality rate 51.5/55.0 42.9/39.8
*
p-value < 0.05 between HCV (+) and HCV(−) in IDUs
♦
p-value < 0.05 between HCV(+) and HCV(−) in No-IDUs
♦♦
p-value < 0.01between HCV(+) and HCV(−) in No-IDUs
PJP H: Pneumocystis jirovecii Pneumonia
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Table 3
Cox proportional hazard regression analysis: Mortality in 356 HIV infected patients
Parameter Mortality risks 95% C.I.* p -value
Female 1.033 0.715–1.492 0.864
IDU 1.069 0.708–1.614 0.751
CD4+ cells count < 200 2.446 1.471–3.581 < 0.01
PJPH 1.784 0.931–3.418 0.08
PJPH prophylaxis 0.751 0.492–1.146 0.185
Cerebral toxoplasmosis 1.483 0.830–2.647 0.183
Wasting syndrome 3.566 2.431–5.228 < 0.01
Hepatitis C 1.167 0.790–1.724 0.437
HAART at enrollment 0.802 0.568–1.132 0.201
C.I. = Confidence Interval
PJPH= Pneumocystis jirovecii Pneumonia
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Table 4







  Male 83.5 57.7 < 0.01
Mean time (years)
  Mean age at death 40.8 37.6 0.059
  Mean time of follow up 1.28 0.88 0.05
  Mean HIV duration 4.1 3.2 0.11
Risk Factor (%)
  IDU 87.6 31.0 < 0.01
  Man with man sex 6.2 29.3 < 0.01
AIDS (%)
  At enrollment 68.0 88.7 < 0.01
Treatments (%)
  HAART at enrollment 40.2 36.6 0.637
  PJP prophylaxis at enrollment 17.5 23.9 0.306
Death causes (%)
  Cardio vascular conditions 9.3 9.9 0.899
  Pulmonary conditions 38.1 57.7 0.012
  Gastro intestinal conditions 28.9 9.9 0.003
  Liver damage 19.6 1.4 < 0.01
  Renal condition 8.2 7.0 0.773
  Metabolic conditions 10.3 7.0 0.463
  Neurological conditions 7.2 9.9 0.540
  Drug overdose-Poisson 10.3 1.4 0.021
  PJPH 3.1 5.6 0.416
  Cerebral toxoplasmosis 8.2 12.7 0.347
  Wasting syndrome 5.2 9.9 0.242
PJPH= Pneumocystis jirovecii Pneumonia
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